-
Altstein A D, Gitelman A K, Smirnov Y A. Immunization with influenza a np-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses[J]. Arch Virol, 2006, 151(5): 921-931. doi: 10.1007/s00705-005-0676-9
-
Barefoot B E, Sample C J, Ramsburg E A. Recombinant vesicular stomatitis virus expressing influenza nucleoprotein induces cd8 t-cell responses that enhance antibody-mediated protection after lethal challenge with influenza virus[J]. Clin Vaccine Immunol, 2009, 16(4): 488-498. doi: 10.1128/CVI.00451-08
-
Biesova Z, Miller M A, Schneerson R. Preparation, characterization, and immunogenicity in mice of a recombinant influenza h5 hemagglutinin vaccine against the avian h5n1 a/vietnam/1203/2004 influenza virus[J]. Vaccine, 2009, 27(44): 6234-6238. doi: 10.1016/j.vaccine.2009.07.107
-
Brands R, Visser J, Medema J. Influvac: A safe madin darby canine kidney (mdck) cell culture-based influenza vaccine[J]. Dev Biol Stand, 1999, 98(): 93-100.
-
Brett I C, Johansson B E. Immunization against influenza a virus: Comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system[J]. Virology, 2005, 339(2): 273-280. doi: 10.1016/j.virol.2005.06.006
-
Chen B J, Leser G P, Morita E. Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles[J]. J Virol, 2007, 81(13): 7111-7123. doi: 10.1128/JVI.00361-07
-
Couch R B, Cate T R. Managing influenza in older patients[J]. Geriatrics, 1983, 38(9): 61-74.
-
Cox M M. Cell-based protein vaccines for influenza[J]. Curr Opin Mol Ther, 2005, 7(1): 24-29.
-
Cox M M, Hollister J R. Flublok, a next generation influenza vaccine manufactured in insect cells[J]. Biologicals, 2009, 37(3): 182-189. doi: 10.1016/j.biologicals.2009.02.014
-
Cox M M, Patriarca P A, Treanor J. Flublok, a recombinant hemagglutinin influenza vaccine[J]. Influenza Other Respi Viruses, 2008, 2(6): 211-219. doi: 10.1111/irv.2008.2.issue-6
-
Cox M M J, Karl Anderson D. Production of a novel influenza vaccine using insect cells: Protection against drifted strains[J]. Influenza Other Respi Viruses, 2007, 1(1): 35-40. doi: 10.1111/j.1750-2659.2006.00007.x
-
D'Aoust M A, Lavoie P O, Couture M M. Influenza virus-like particles produced by transient expression in nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice[J]. Plant Biotechnol J, 2008, 6(9): 930-940. doi: 10.1111/pbi.2008.6.issue-9
-
De Filette M, Martens W, Smet A. Universal influenza a m2e-hbc vaccine protects against disease even in the presence of pre-existing anti-hbc antibodies[J]. Vaccine, 2008, 26(51): 6503-6507. doi: 10.1016/j.vaccine.2008.09.038
-
Denis J, Acosta-Ramirez E, Zhao Y. Development of a universal influenza a vaccine based on the m2e peptide fused to the papaya mosaic virus (papmv) vaccine platform[J]. Vaccine, 2008, 26(27): 3395-3403.
-
Doherty P C, Turner S J, Webby R G. Influenza and the challenge for immunology[J]. Nat Immunol, 2006, 7(5): 449-455. doi: 10.1038/ni1343
-
Fiers W, De Filette M, Birkett A. A " universal" human influenza a vaccine[J]. Virus Res, 2004, 103(1-2): 173-176. doi: 10.1016/j.virusres.2004.02.030
-
Gavrilov V, Orekov T, Alabanza C. Influenza virus-like particles as a new tool for vaccine immunogenicity testing: Validation of a neuraminidase neutralizing antibody assay[J]. J Virol Methods, 2011, 173(2): 364-373. doi: 10.1016/j.jviromet.2011.03.011
-
Gerdil C. The annual production cycle for influenza vaccine[J]. Vaccine, 2003, 21(16): 1776-1779. doi: 10.1016/S0264-410X(03)00071-9
-
Govorkova E A, Leneva I A, Goloubeva O G. Comparison of efficacies of rwj-270201, zanamivir, and oseltamivir against h5n1, h9n2, and other avian influenza viruses[J]. Antimicrob agents ch, 2001, 45(10): 2723-2732. doi: 10.1128/AAC.45.10.2723-2732.2001
-
Grandea A G, Olsen O A, Cox T C. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza a viruses[J]. Proc Natl Acad Sci USA, 2010, 107(28): 12658-12663. doi: 10.1073/pnas.0911806107
-
Holmes E C, Ghedin E, Miller N. Whole-genome analysis of human influenza a virus reveals multiple persistent lineages and reassortment among recent h3n2 viruses[J]. Plos Biology, 2005, 3(9): e300-. doi: 10.1371/journal.pbio.0030300
-
Holsinger L J, Alams R. Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds[J]. Virology, 1991, 183(1): 32-43. doi: 10.1016/0042-6822(91)90115-R
-
Holtz K M, Anderson D K, Cox M M J. Production of a recombinant influenza vaccine using the baculovirus expression vector system[J]. Bioprocess J, 2003, 2(): 25-32. doi: 10.12665/issn.1538-8786
-
Bac-to-bac® baculovirus expression system. 2010. An efficient site-specific transposition system to generate baculovirus for high-level expression of recombinant proteins. Invitrogen. p1-69.
-
Johansson B, Kilbourne E. Immunization with purified n1 and n2 influenza virus neuraminidases demonstrates cross-reactivity without antigenic competition[J]. Proc Natl Acad Sci USA, 1994, 91(6): 2358-. doi: 10.1073/pnas.91.6.2358
-
Johansson B E, Brett I C. Changing perspective on immunization against influenza[J]. Vaccine, 2007, 25(16): 3062-3065. doi: 10.1016/j.vaccine.2007.01.030
-
Johansson B E, Price P M, Kilbourne E D. Immunogenicity of influenza-a virus n2 neuraminidase produced in insect larvae by baculovirus recombinants[J]. Vaccine, 1995, 13(9): 841-845. doi: 10.1016/0264-410X(94)00071-T
-
Johansson B E, Pokorny B A, Tiso V A. Supplementation of conventional trivalent influenza vaccine with purified viral n1 and n2 neuraminidases induces a balanced immune response without antigenic competition[J]. Vaccine, 2002, 20(11-12): 1670-1674. doi: 10.1016/S0264-410X(01)00490-X
-
Khurana S, Wu J, Verma N. H5n1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans[J]. J Virol, 2011, 85(21): 10945-10954. doi: 10.1128/JVI.05406-11
-
Kilbourne E D, Cerini C, Khan M. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees[J]. J Immunol, 1987, 138(9): 3010-.
-
Kilbourne E D, Pokorny B A, Johansson B. Protection of mice with recombinant influenza virus neuraminidase[J]. J Infect Dis, 2004, 189(3): 459-461. doi: 10.1086/jid.2004.189.issue-3
-
Lamb R, Krug R. 2001. Orthomyxoviridae: The viruses and their replication. In: Fields Virology. Knipe D N, Howley P M, Griffin D E, et al, ed. Philadelphia: Lippincott Williams and Wilkins Publishers, pp1487-1532.
-
Lopez-Macias C, Ferat-Osorio E, Tenorio-Calvo A, et al. 2011. Safety and immunogenicity of a virus-like particle pandemic influenza a (h1n1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in mexico. Vaccine, doi: 10.1016/j.vaccine.2011.07.099.
-
Mahmood K, Bright R A, Mytle N. H5n1 vlp vaccine induced protection in ferrets against lethal challenge with highly pathogenic h5n1 influenza viruses[J]. Vaccine, 2008, 26(42): 5393-5399. doi: 10.1016/j.vaccine.2008.07.084
-
McKimm-Breschkin J, Trivedi T, Hampson A. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir[J]. Antimicrob Agents Ch, 2003, 47(7): 2264-2272. doi: 10.1128/AAC.47.7.2264-2272.2003
-
Mena I, Jambrina E, Albo C. Mutational analysis of influenza a virus nucleoprotein: Identification of mutations that affect rna replication[J]. J Virol, 1999, 73(2): 1186-1194.
-
Murphy B R, Kasel J A, Chanock R M. Association of serum anti-neuraminidase antibody with resistance to influenza in man[J]. New Engl J Med, 1972, 286(25): 1329-1332. doi: 10.1056/NEJM197206222862502
-
Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin h1n1 influenza virus[J]. Nature, 2009, 459(7249): 931-939. doi: 10.1038/nature08157
-
Pau M G, Ophorst C, Koldijk M H. The human cell line per.C6 provides a new manufacturing system for the production of influenza vaccines[J]. Vaccine, 2001, 19(17-19): 2716-2721. doi: 10.1016/S0264-410X(00)00508-9
-
Pinto L H, Lamb R A. The m2 proton channels of influenza a and b viruses[J]. J Biol Chem, 2006, 281(14): 8997-9000. doi: 10.1074/jbc.R500020200
-
Pleschka S, Ludwig S, Wolff T, et al. 2006. Anti-viral approaches against influenza viruses. New Concepts of Antiviral Therapy, 115-167.
-
QIAexpressionist A. 2002 A handbook for high-level expression and purification of 6xhis-tagged proteins. Qiagen. p1-125.
-
Quan F S, Huang C, Compans R W. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus[J]. J Virol, 2007, 81(7): 3514-3524. doi: 10.1128/JVI.02052-06
-
Roldao A, Mellado M C, Castilho L R. Virus-like particles in vaccine development[J]. Expert Rev Vaccines, 2010, 9(10): 1149-1176. doi: 10.1586/erv.10.115
-
Schotsaert M, De Filette M, Fiers W. Universal m2 ectodomain-based influenza a vaccines: Preclinical and clinical developments[J]. Expert Rev Vaccines, 2009, 8(4): 499-508. doi: 10.1586/erv.09.6
-
Sylte M J, Suarez D L. 2009. Influenza neuraminidase as a vaccine antigen. In: Vaccines for Pandemic Influenza. Compans R W, Orenstein W A, eds. Heidelberg: Springer, p227-241.
-
Szecsi J, Boson B, Johnsson P. Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic h5n1 and h7n1 influenza viruses[J]. Virol J, 2006, 3(): 70-. doi: 10.1186/1743-422X-3-70
-
Treanor J J, Schiff G M, Hayden F G. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: A randomized controlled trial[J]. JAMA, 2007, 297(14): 1577-1582. doi: 10.1001/jama.297.14.1577
-
Wang K, Holtz K M, Anderson K. Expression and purification of an influenza hemagglutinin—one step closer to a recombinant protein-based influenza vaccine[J]. Vaccine, 2006, 24(12): 2176-2185. doi: 10.1016/j.vaccine.2005.11.005
-
Wang R, Song A, Levin J. Therapeutic potential of a fully human monoclonal antibody against influenza a virus m2 protein[J]. Antiviral Res, 2008, 80(2): 168-177. doi: 10.1016/j.antiviral.2008.06.002
-
Webster R G, Bean W J, Gorman O T. Evolution and ecology of influenza-a viruses[J]. Microbiol Rev, 1992, 56(1): 152-179.
-
Weldon W C, Wang B Z, Martin M P. Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin[J]. PLoS One, 2010, 5(9): -.
-
Wu C Y, Yeh Y C, Yang Y C. Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus[J]. PLoS One, 2010, 5(3): e9784-. doi: 10.1371/journal.pone.0009784
-
Youil R, Su Q, Toner T J. Comparative study of influenza virus replication in vero and mdck cell lines[J]. J Virol Methods, 2004, 120(1): 23-31. doi: 10.1016/j.jviromet.2004.03.011